Safety of sodium-glucose cotransporter 2 inhibitors in kidney transplant recipients with diabetes mellitus
In KTRs with diabetes, SGLT2i therapy improved glycemic control without increased safety concerns compared to standard treatments. Both groups exhibited similar risks of significant kidney-related events and all-cause mortality. These findings provide crucial insights into the existing limited data concerning this vulnerable population, which faces elevated risks of renal complications and medication-related adverse effects. Ongoing randomized controlled trials will provide additional safety data for SGLT2i in KTRs.
Authors
- I. Bergman
- Idit Dotan (ORCID: https://orcid.org/0000-0003-0551-4759)
- Gida Ayada
- Amit Akirov (ORCID: https://orcid.org/0000-0002-9376-344X)
- Talia Diker‐Cohen (ORCID: https://orcid.org/0000-0001-6211-2073)
- Tanya Babich
- Tali Steinmetz (ORCID: https://orcid.org/0000-0002-5377-9156)
- Amir Polansky
Institutions
- Technion – Israel Institute of Technology (IL)
- Rabin Medical Center (IL)
- Rambam Health Care Campus (IL)
- Rappaport Family Institute for Research in the Medical Sciences (IL)
Publication Details
- Journal
- Diabetes & Metabolism
- Published
- 2025-02-15
- DOI
- https://doi.org/10.1016/j.diabet.2025.101627
- Citations
- 8
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 10.36